Vericiguat (BAY1021189)
Sponsors
Bayer
Conditions
Coronary Artery DiseaseHeart Failure
Phase 1
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
CompletedNCT02617550
Start: 2015-11-18End: 2016-08-11Updated: 2021-12-29
Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients
CompletedNCT03255512
Start: 2017-08-17End: 2018-03-23Updated: 2021-12-29
Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat
CompletedNCT03504982
Start: 2018-05-17End: 2019-02-26Updated: 2020-04-17
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
CompletedNCT04722484
Start: 2014-06-12End: 2015-01-22Updated: 2021-01-25
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants
CompletedNCT04722562
Start: 2014-07-16End: 2015-04-30Updated: 2021-01-25